Cargando…

Considering adjuvant therapy for stage II melanoma

Melanoma is among the few cancers that demonstrate an increasing incidence over time. Simultaneously, this trend has been marked by an epidemiologic shift to earlier stage at diagnosis. Before 2011, treatment options were limited for patients with metastatic disease, and the median overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poklepovic, Andrew S., Luke, Jason J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065103/ https://www.ncbi.nlm.nih.gov/pubmed/31869447 http://dx.doi.org/10.1002/cncr.32585

Ejemplares similares

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

For Stage II Node-Positive Breast Cancer, is it Worthwhile to Consider Adjuvant Radiotherapy Following Mastectomy?
por: Osman, Mohammed A. M., et al.
Publicado: (2014)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
por: Testori, Alessandro A. E., et al.
Publicado: (2020)

Factors associated with the use of adjuvant radiation therapy in stage III melanoma
por: King, Amber L. O., et al.
Publicado: (2023)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
por: De Falco, Vincenzo, et al.
Publicado: (2021)

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
por: Eljilany, Islam, et al.
Publicado: (2023)

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
por: Luke, Jason J, et al.
Publicado: (2014)

The Importance of Considering Alexithymia during Initial Stages of Intimate Partner Violence Interventions to Design Adjuvant Treatments
por: Romero Martínez, Ángel, et al.
Publicado: (2019)

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
por: Donada, Marisa, et al.
Publicado: (2013)

ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma
por: Bloemendal, Martine, et al.
Publicado: (2019)

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study
por: Moncrieff, Marc D., et al.
Publicado: (2022)

Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies to Promote the Anti-Tumor Immune Response
por: Pelka, Sandra, et al.
Publicado: (2023)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
por: Okuyama, Sonia, et al.
Publicado: (2010)

Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis
por: Benson, Zachary, et al.
Publicado: (2017)

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma
por: Derks, S.H.A.E., et al.
Publicado: (2022)

Targeted Therapy; From Advanced Melanoma to the Adjuvant Setting
por: Ahn, Antonio, et al.
Publicado: (2013)

Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer
por: Ma, Sung Jun, et al.
Publicado: (2019)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
por: Garbe, Claus, et al.
Publicado: (2022)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy
por: Buras, Andrea L., et al.
Publicado: (2021)

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
por: Mohr, Peter, et al.
Publicado: (2019)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer
por: Zhu, Ning, et al.
Publicado: (2022)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5neij0nc4k6mcmkeier9kqptoc